HDAC9 and thyroid gland carcinoma: In general, despite the fact that preclinical trials demonstrated the proliferation-inhibiting and differentiation-inducing effects of HDAC inhibitors in thyroid cancer, clinical trials with these inhibitors gave unsatisfactory results (Table 2).